Plant Comparison

Hawthorn vs Perforate St John’s-wort

A side-by-side comparison of two medicinal plants - every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.

First plant
Second plant
Show:
Plant AHawthornCrataegus monogynaRosaceaeFull monograph →
Plant BPerforate St John’s-wortHypericum perforatumHypericaceaeFull monograph →

At a glance

Hawthorn and Perforate St John’s-wort: they share 4 indicated uses (arthritis / joint pain, inflammation (general), insomnia / sleeplessness, …); 3 pharmacological actions in common.

HawthornPerforate St John’s-wort
Constituents23
Pharmacological actions46
Indicated uses69
Safety notes22
Cited sources2332
Indicated uses
Only Hawthorn
Cancer (anticancer research)Cardiovascular / heart health
Shared (4)
Arthritis / joint painInflammation (general)Insomnia / sleeplessnessSkin irritation
Only Perforate St John’s-wort
BruisingCold & fluEczemaInfection (general)Wounds
Pharmacological actions
Only Hawthorn
Anticancer (preclinical)
Shared (3)
Anti-inflammatoryAntioxidantSedative / sleep support
Only Perforate St John’s-wort
AntiviralEmollient / skin-soothingVulnerary (wound healing)

Evidence face-off - shared uses

ConditionHawthornPerforate St John’s-wortVerdict
Arthritis / joint pain1/101/10Comparable evidence
Inflammation (general)1/101/10Comparable evidence
Insomnia / sleeplessness1/101/10Comparable evidence
Skin irritation1/101/10Comparable evidence

Evidence scores (1-10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.

Key Constituents

Flavonoids (catechins, quercetin, vitexin) and anthocyanins[1, 4]

Principal cardioprotective and antioxidant polyphenols characterised by chemical profiling of leaf, flower and fruit.

FlavonoidsCatechinsQuercetinAnthocyanins
Oligomeric proanthocyanidins[4]

Contribute to the vasoactive and antioxidant effects, the basis for extract standardisation.

Proanthocyanidins
Naphthodianthrones (hypericin, pseudohypericin)[4]

Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.

Phloroglucinols (hyperforin)[4]

Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.

Hyperforin
Flavonoids (hyperoside, quercetin, rutin)[4]

Antioxidant flavonoids contributing to overall activity.

FlavonoidsQuercetinRutin

Pharmacological Actions

Anti-inflammatory[4, 15, 16, 17]
Anticancer (preclinical)[1]
Antioxidant[4, 5, 6, 9, 10, 11, 12, 15, 16, 17]
Sedative / sleep support[15, 16, 17]
Anti-inflammatory[5, 16, 17]
Antioxidant[6, 16, 17]
Antiviral[16, 17]
Emollient / skin-soothing[16, 17]
Sedative / sleep support[1, 2, 4, 5, 9, 11, 12, 13, 14, 16, 17]
Vulnerary (wound healing)[4, 16, 17]

Traditional & Indicated Uses

Arthritis / joint pain[15, 16, 17]Preliminary · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Cancer (anticancer research)[1]Preliminary · 2/10

inferred from anticancer action

Evidence: 2
Label: Cancer (anticancer research)
Cardiovascular / heart health[15, 16, 17]Preliminary · 1/10
Evidence: 1
Label: Cardiovascular / heart health
Inflammation (general)[15, 16, 17]Preliminary · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Inflammation (general)
Insomnia / sleeplessness[15, 16, 17]Preliminary · 1/10

inferred from sedative action

Evidence: 1
Label: Insomnia / sleeplessness
Skin irritation[15, 16, 17]Preliminary · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation
Arthritis / joint pain[16, 17]Preliminary · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Arthritis / joint pain
Bruising[16, 17]Preliminary · 1/10

inferred from vulnerary action

Evidence: 1
Label: Bruising
Cold & flu[16, 17]Preliminary · 1/10

inferred from antiviral action

Evidence: 1
Label: Cold & flu
Eczema[16, 17]Preliminary · 1/10

inferred from emollient action

Evidence: 1
Label: Eczema
Infection (general)[16, 17]Preliminary · 1/10

inferred from antiviral action

Evidence: 1
Label: Infection (general)
Inflammation (general)[16, 17]Preliminary · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Inflammation (general)
Insomnia / sleeplessness[16, 17]Preliminary · 1/10

inferred from sedative action

Evidence: 1
Label: Insomnia / sleeplessness
Skin irritation[16, 17]Preliminary · 1/10

inferred from anti-inflammatory action

Evidence: 1
Label: Skin irritation
Wounds[16, 17]Preliminary · 1/10

inferred from vulnerary action

Evidence: 1
Label: Wounds

Safety, Cautions & Contraindications

Safety note[15, 16, 17]Caution

Generally well tolerated. Hawthorn should not replace prescribed cardiac medications without medical supervision. May potentiate the effects of cardiac glycosides (digoxin), antihypertensive drugs, and coronary dilators. Not recommended during pregnancy and breastfeeding due to insufficient safety data. Mild side effects (nausea, dizziness, GI upset) occasionally reported.

Safety note[15, 16, 17, 18]Caution

Duke (2002) rates hawthorn as +++ - one of the most clinically supported cardiovascular herbs. Clinical evidence (score 2) supports its use for decreasing cardiac output (NYHA functional Stage II heart failure), as recognized by Commission E. Key activities include vasodilation, positive inotropic effects, and antioxidant protection of vascular tissue. Dose: 160–900 mg standardized leaf/flower extract (containing 18.75% oligomeric proanthocyanidins) daily. Duke emphasizes that hawthorn should not replace conventional heart failure therapy, and therapeutic effects may take 4–8 weeks to emerge. Mild interactions with cardiac glycosides (digitalis) are possible (Duke, 2002).

Safety note[16, 17]Caution

Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.

Safety note[16, 17, 18]Caution

Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).

External Ids

Gbif: 9220780
Wikidata: Q161511
Gbif: 3189486
Powo: urn:lsid:ipni.org:names:433719-1
Wikidata: Q158289

Botanical Description

Small deciduous tree or large shrub, densely thorny, with deeply lobed, glossy leaves (more deeply cut than midland hawthorn). Clusters of small, five-petalled white flowers with a strong, musky scent appear in spring ('May blossom'), followed by small red berries (haws), each containing a single seed (nutlet) - the origin of the species name monogyna.[4]

Height: 5-10 m
Habit: Small deciduous, densely thorny tree or large shrub
Leaves: Deeply lobed, glossy (more deeply cut than C. laevigata)
Flowers: Clusters of small, five-petalled white, strongly musky-scented flowers
Stem: Densely thorny branches; grey, fissured bark on older wood
Root: Deep, spreading root system
Fruit: Small red berry (haw), containing a single seed
Flowering Period: May

Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]

Height: 30-90 cm
Habit: Erect, branching perennial herb
Leaves: Paired, oval, dotted with tiny translucent oil glands
Flowers: Bright yellow, five-petalled, with numerous stamens and black-dotted petal edges, in flat-topped clusters
Stem: Erect, branching, with two raised longitudinal ridges
Root: Woody rootstock with spreading rhizomes
Fruit: Small, three-valved capsule
Flowering Period: June-September (traditionally around St John's Day, 24 June)

Habitat

One of the commonest hedgerow and scrub trees of Europe, growing in hedgerows, woodland edges, scrub and pasture on a wide range of soils; native to Europe, North Africa and Western Asia.[4]

Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]

Harvesting

Flowers are picked as they open in May, leaves are picked with the young flowering shoots, and the ripe red berries (haws) are gathered in autumn after the first frosts soften them slightly; all three parts are traditionally combined.[4]

Parts: Flower, Fruit, Leaf
Season: Flower and leaf in May; fruit in autumn

The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]

Parts: Flower, Leaf
Season: Summer, at flowering

Harvest Readiness

[13, 14]

Part: flower
Signals: Gather the flowering tops (creamy blossom with the young leaves) in spring, as the blossom opens.
Basis: traditional
Source Quote: an explosion of pretty pale-pink blossom in May
Independent Confirmation: PFAF (REF-3238) 'It is in flower from May to June' independently confirms the Woodland Trust (REF-3237) spring-blossom stage; two independent prisms agree.
Species Confirmed: 1
Notes: Woodland Trust (REF-3237) 'blossom in May' and PFAF (REF-3238) 'in flower from May to June' both place flowering in spring; the flowering tops are gathered as folium cum flore with the young leaf.

[13]

Part: leaf
Signals: Gather the young leaves in spring as they emerge, among the first of the hedgerow, with the flowering shoots.
Basis: traditional
Source Quote: The pale green leaves of this hedgerow staple are often the first to appear in spring
Species Confirmed: 1
Notes: Woodland Trust (REF-3237); the young leaf is among the first to appear in spring and is gathered with the flowering shoots (folium cum flore). Single source for the leaf specifically -> provisional.

[14]

Part: fruit
Signals: Gather the haws in autumn as they ripen to deep red, following the flowers.
Basis: traditional
Source Quote: It is in flower from May to June, and the seeds ripen from September to November.
Species Confirmed: 1
Notes: PFAF (REF-3238); the haws ripen in autumn ('seeds ripen from September to November'; 'Hawthorn berries are typically harvested in late Summer to early Autumn'). Woodland Trust gave no fruit-ripening stage. Single source -> provisional.

[15]

Part: flower
Signals: Cut the flowering tops in mid-summer, when the flowers are in full bloom.
Basis: traditional
Source Quote: The flowering tops are harvested in mid-summer when the flowers are in full bloom.
Species Confirmed: 1
Notes: PFAF (REF-3274); the flowering tops are cut at full bloom in mid-summer (in flower May-August). Single lineage -> provisional.

[15]

Part: leaf
Signals: Gather the leaves with the flowering tops in mid-summer, at full bloom.
Basis: traditional
Source Quote: The flowering tops are harvested in mid-summer when the flowers are in full bloom.
Species Confirmed: 1
Notes: PFAF (REF-3274); the leaf is gathered with the flowering tops at full bloom. Single lineage -> provisional.

Traditional Uses

Common hawthorn shares the same long cardiovascular and calming tradition as midland hawthorn, used across European herbal medicine as a heart tonic for mild circulatory complaints, palpitations and nervous tension, and remains one of the most clinically studied cardiovascular botanicals.[4]

St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]

Preparations

Standardised extract[4]

Leaf-and-flower extract standardised to flavonoid or procyanidin content, taken as tablets or capsules; the best-studied clinical form.

Standardised extract[1]

Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.

Dosage

Standardised extract[15]

The EU herbal monograph on Crataegus spp., folium cum flore gives dry extracts in divided daily doses of 240-900 mg (single dose 80-450 mg) or, for one quantified extract, 570-1750 mg daily (single dose 190-350 mg), in adults and elderly. If symptoms persist longer than 2 weeks a doctor should be consulted, and hawthorn is never used as a substitute for prescribed heart medication without medical supervision. Educational reference only, not a prescription.

Herbal tea[15]

The EU herbal monograph gives 1-2 g of the comminuted leaf and flower in 150 mL of boiling water as an infusion, up to 4 times daily (maximum 6 g daily), in adults and elderly. Educational reference only, not a prescription.

Standardised extract[1]

Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.

References

REF-0785, REF-0786, REF-0787, REF-1709, REF-1710, REF-1711, REF-1712, REF-1713, REF-1714, REF-1715, REF-1716, REF-1717
REF-0842, REF-0843, REF-0844, REF-1789, REF-1790, REF-1791, REF-1792, REF-1793, REF-1794, REF-1795, REF-1796, REF-1797, REF-1798, REF-1799

Drug Class Interactions

Cardiac Glycosides[19, 20, 21]Caution
Mechanism: Hawthorn has its own positive effect on the heart (a Cochrane review found it improves heart-failure symptoms and exercise tolerance) and shares P-glycoprotein handling with digoxin, so combining it with digoxin or other cardiac-glycoside heart drugs should be supervised even though a controlled study found no major change in digoxin levels.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Antihypertensives[20, 21]Caution
Mechanism: Hawthorn can mildly lower blood pressure and reduce cardiac oxygen demand (a Cochrane meta-analysis found a lower pressure-heart-rate product), which may add to the effect of blood-pressure and heart-failure medicines.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Sedatives Cns Depressants[22, 23]Caution
Mechanism: Hawthorn is traditionally used as a calming, sedative herb; taken with sedatives, sleeping tablets or other central-nervous-system depressants (including alcohol) it may add to drowsiness and slowed reactions.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Antidepressants Serotonergic[19, 20, 21, 22]Avoid
Mechanism: St John's wort raises serotonin activity; combined with SSRIs, SNRIs or MAOIs it can trigger serotonin syndrome (agitation, tremor, sweating, rapid heartbeat). Reviews of clinical reports document serotonin syndrome and lethargy when it is combined with serotonin-reuptake inhibitors.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Antiretrovirals[19, 20, 23]Avoid
Mechanism: Potent CYP3A4 and P-glycoprotein induction lowers antiretroviral levels (indinavir exposure fell ~57%), risking loss of viral control and drug resistance.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Immunosuppressants[19, 20, 24]Avoid
Mechanism: Enzyme and transporter induction reduces ciclosporin and tacrolimus levels; reported to cause subtherapeutic concentrations and transplant rejection.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Hormonal Therapies[19, 25, 26, 27]Avoid
Mechanism: Increased metabolism of ethinylestradiol and progestins reduces contraceptive exposure, causing breakthrough bleeding, ovulation and unplanned pregnancy. Randomised and controlled trials in women confirmed more breakthrough bleeding, reduced progestin levels and evidence of ovulation when St John's wort was added to the pill.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Anticoagulants Antiplatelets[19, 20, 22]Caution
Mechanism: CYP induction increases warfarin clearance and can lower INR, reducing the anticoagulant effect; close monitoring is needed.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Cardiac Glycosides[19, 28]Caution
Mechanism: P-glycoprotein induction lowers digoxin levels (AUC fell ~25% over ten days), which may reduce its effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Statins[19, 20, 22]Caution
Mechanism: CYP3A4 induction lowers levels of simvastatin and atorvastatin, potentially weakening their cholesterol-lowering effect.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Cyp3a4 Substrates[19, 20, 22]Caution
Mechanism: As a broad CYP3A4 and P-glycoprotein inducer, St John's wort can lower levels of many medicines cleared by this pathway; check each medication individually.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Chemotherapy Agents[21, 29, 30]Avoid
Mechanism: St John's wort strongly induces CYP3A4 and P-glycoprotein, speeding the breakdown and removal of several cancer medicines. In patients it cut the active form of irinotecan (SN-38) by about 42% and reduced imatinib exposure by roughly a third - enough to weaken treatment and risk drug resistance. Do not take St John's wort during chemotherapy.
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

Lookalikes Review

Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07
Outcome: none-known
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-07

Pairings

Not documented

Crocus Sativus[31]

St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.

Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Rhodiola Rosea[31]

St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.

Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Valeriana Officinalis[31, 32]

St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.

Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03
Piper Methysticum[31, 32]

St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.

Type: caution
Reviewed By: Omnia Sana (owner-authorized)
Reviewed Date: 2026-07-03

References & Sources

  1. Ez-Zahra Amrati, F., Mssillou, I., Boukhira, S., Djiddi Bichara, M. et al (2024) 'Phenolic Composition of Crataegus monogyna Jacq. Extract and Its Anti-Inflammatory, Hepatoprotective, and Antileukemia Effects', Pharmaceuticals (Basel), 17(6), pp. 786. doi:10.3390/ph17060786 Preclinical
    https://doi.org/10.3390/ph17060786
  2. Lis, M., Szczypka, M., Suszko-Pawłowska, A., Sokół-Łętowska, A. et al (2019) 'Hawthorn (Crataegus monogyna) Phenolic Extract Modulates Lymphocyte Subsets and Humoral Immune Response in Mice', Planta Medica, 86(2), pp. 160-168. doi:10.1055/a-1045-5437 Preclinical
    https://doi.org/10.1055/a-1045-5437
  3. Paun, G., Neagu, E., Albu, C., Alecu, A. et al (2024) 'Antioxidant and Antidiabetic Activity of Crataegus monogyna L. and Cornus mas Fruit Extracts', Molecules, 29(15), pp. 3595. doi:10.3390/molecules29153595 Preclinical
    https://doi.org/10.3390/molecules29153595
  4. Nabavi, S.F., Habtemariam, S., Ahmed, T., Sureda, A., Daglia, M. and Sobarzo-Sanchez, E (2015) 'Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications', Nutrients, 7(9), pp. 7708-7728. doi:10.3390/nu7095361 Meta-analysis / review
    https://doi.org/10.3390/nu7095361
  5. Belabdelli, F., Bekhti, N., Piras, A., Benhafsa, F.M., Ilham, M. and Adil, S (2021) 'Chemical composition, antioxidant and antibacterial activity of Crataegus monogyna leaves' extracts', Natural Product Research, 36(12), pp. 3234-3239. doi:10.1080/14786419.2021.1958215 Preclinical
    https://doi.org/10.1080/14786419.2021.1958215
  6. Jalali, A.S., Hasanzadeh, S. and Malekinejad, H (2012) 'Crataegus monogyna aqueous extract ameliorates cyclophosphamide-induced toxicity in rat testis: stereological evidences', Acta Medica Iranica, 50(1), pp. 1-8. Preclinical
    https://scholar.google.com/scholar?q=Crataegus%20monogyna%20aqueous%20extract%20ameliorates%20cyclophosphamide-induced%20toxicity%20in%20rat%20testis%3A%20stereological%20evidences
  7. Martin-Garcia, B., Razola-Diaz, M.D.C., Gomez-Caravaca, A.M., Benitez, G. and Verardo, V (2021) 'Setup of an Ultrasonic-Assisted Extraction to Obtain High Phenolic Recovery in Crataegus monogyna Leaves', Molecules, 26(15), pp. 4536. doi:10.3390/molecules26154536 Preclinical
    https://doi.org/10.3390/molecules26154536
  8. Arslan, R., Bektas, N., Bor, Z. and Sener, E (2014) 'Evaluation of the antithrombotic effects of Crataegus monogyna and Crataegus davisii in the carrageenan-induced tail thrombosis model', Pharmaceutical Biology, 53(2), pp. 275-279. doi:10.3109/13880209.2014.914957 Preclinical
    https://doi.org/10.3109/13880209.2014.914957
  9. Edwards, J.E., Brown, P.N., Talent, N., Dickinson, T.A. and Shipley, P.R (2012) 'A review of the chemistry of the genus Crataegus', Phytochemistry, 79, pp. 5-26. doi:10.1016/j.phytochem.2012.04.006 Meta-analysis / review
    https://doi.org/10.1016/j.phytochem.2012.04.006
  10. Jarzycka, A., Lewinska, A., Gancarz, R. and Wilk, K.A (2013) 'Assessment of extracts of Helichrysum arenarium, Crataegus monogyna, Sambucus nigra in photoprotective UVA and UVB; photostability in cosmetic emulsions', Journal of Photochemistry and Photobiology B: Biology, 128, pp. 50-57. doi:10.1016/j.jphotobiol.2013.07.029 Preclinical
    https://doi.org/10.1016/j.jphotobiol.2013.07.029
  11. Lucconi, G., Chlapanidas, T., Martino, E., Gaggeri, R., Perteghella, S. and Rossi, D (2013) 'Formulation of microspheres containing Crataegus monogyna Jacq. extract with free radical scavenging activity', Pharmaceutical Development and Technology, 19(1), pp. 65-72. doi:10.3109/10837450.2012.752387 Preclinical
    https://doi.org/10.3109/10837450.2012.752387
  12. Zorniak, M., Szydlo, B. and Krzeminski, T.F (2017) 'Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences', Journal of Physiology and Pharmacology, 68(4), pp. 521-526. Meta-analysis / review
    https://scholar.google.com/scholar?q=Crataegus%20special%20extract%20WS%201442%3A%20up-to-date%20review%20of%20experimental%20and%20clinical%20experiences
  13. Woodland Trust 'Hawthorn (Crataegus monogyna)'. Available at: https://www.woodlandtrust.org.uk/trees-woods-and-wildlife/british-trees/a-z-of-british-trees/hawthorn/ Traditional / reference
    https://www.woodlandtrust.org.uk/trees-woods-and-wildlife/british-trees/a-z-of-british-trees/hawthorn/
  14. Plants For A Future 'Crataegus monogyna (Common Hawthorn, Oneseed Hawthorn)'. Available at: https://pfaf.org/user/Plant.aspx?LatinName=Crataegus+monogyna Traditional / reference
    https://pfaf.org/user/Plant.aspx?LatinName=Crataegus+monogyna
  15. European Medicines Agency (2016) 'European Union herbal monograph on Crataegus spp., folium cum flore'. Traditional / reference
    https://scholar.google.com/scholar?q=European%20Union%20herbal%20monograph%20on%20Crataegus%20spp.%2C%20folium%20cum%20flore
  16. Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure'. Traditional / reference
    https://scholar.google.com/scholar?q=Hawthorn%20extract%20for%20treating%20chronic%20heart%20failure
  17. Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
    https://powo.science.kew.org
  18. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  19. Tankanow, R., Tamer, H.R., Streetman, D.S., Smith, S.G., Welton, J.L., Annesley, T., Aaronson, K.D. and Bleske, B.E (2003) 'Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha)', Journal of Clinical Pharmacology, 43(6), pp. 637-642. doi:10.1177/0091270003253417 Randomized trial
    https://doi.org/10.1177/0091270003253417
  20. Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD005312.pub2
  21. Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
    https://doi.org/10.1002/14651858.CD005312.pub2
  22. Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
    https://doi.org/10.1002/ptr.8201
  23. Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
    https://doi.org/10.1177/1534735404265003
  1. Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
    https://doi.org/10.1016/j.jad.2016.12.048
  2. Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
    https://doi.org/10.1007/s00210-022-02229-z
  3. Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
    https://doi.org/10.1016/S0140-6736(99)06457-0
  4. Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
    https://doi.org/10.22038/IJBMS.2022.65112.14338
  5. Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
    https://doi.org/10.1016/j.phymed.2024.155847
  6. Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
    https://doi.org/10.3389/fpls.2016.01004
  7. Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
    https://doi.org/10.1002/ptr.5050
  8. Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
    https://doi.org/10.1016/j.jep.2010.07.034
  9. Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
    https://doi.org/10.1016/j.lfs.2004.04.005
  10. Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
    https://doi.org/10.3109/13697137.2013.861814
  11. Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
    https://doi.org/10.2165/00003088-200645050-00002
  12. Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
    https://doi.org/10.1055/s-2001-15467
  13. Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
    https://doi.org/10.1038/sj.mp.4000557
  14. Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
    https://doi.org/10.2174/1568026033392589
  15. Plants For A Future 'Hypericum perforatum (St John's Wort)'. Available at: https://pfaf.org/user/Plant.aspx?LatinName=Hypericum+perforatum Traditional / reference
    https://pfaf.org/user/Plant.aspx?LatinName=Hypericum+perforatum
  16. Linde, K. et al (2008) 'St John'. Traditional / reference
    https://scholar.google.com/scholar?q=St%20John
  17. Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
    https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St
  18. Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
    https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
  19. Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
    https://doi.org/10.1177/0269881104042632
  20. Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
    https://doi.org/10.2165/11317010-000000000-00000
  21. Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
    https://doi.org/10.1208/s12248-009-9146-8
  22. Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
    https://doi.org/10.1111/bph.14936
  23. Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
    https://doi.org/10.1016/S0140-6736(99)05712-8
  24. Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
    https://doi.org/10.1345/aph.10088
  25. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  26. Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
    https://doi.org/10.1016/j.contraception.2004.11.004
  27. Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
    https://doi.org/10.1046/j.1365-2125.2003.02005.x
  28. Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
    https://doi.org/10.1053/cp.1999.v66.a101944
  29. Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
    https://doi.org/10.1093/jnci/94.16.1247
  30. Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
    https://doi.org/10.1592/phco.24.16.1508.50958
  31. Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
    https://doi.org/10.5414/cpp42139
  32. Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
    https://doi.org/10.3390/ph19030399

Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only - not medical advice. Always consult a qualified practitioner before using medicinal plants.